Endo enters settlement agreement to resolve opioid claims in Texas
Endo International and subsidiaries have signed a state-wide agreement to pay a total of $63m to settle claims linked to opioids in Texas state of the US.
December 27, 2021
by The payment as part of the deal will be made into the Texas State Qualified Settlement Fund.
Endo Begins Shipment of Generic MIACALCIN® Injection
Endo International plc announced that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the FDA for its Abbreviated New Drug Application.
November 19, 2021
by AmericanPharmaceuticalReview
Strides Pharma Science to acquire Endo’s manufacturing facility in US
Strides said the facility at Chestnut Ridge, New York has an annual capacity of two billion units across semi-solids, liquids and nasal sprays, along with oral solids.
August 9, 2021
by expresspharma
Endo agrees opioid settlement payment with Oklahoma for $8.75m
The US state of Oklahoma has agreed to a settlement from Endo International after an investigation into its role in the opioid abuse crisis.
January 15, 2020
by europeanpharmaceuticalreview
Endo and Allergan settle opioid case ahead of trial
The two pharma companies have agreed to pay $15 million to certain Ohio counties before an opioid abuse trial to be held in October.
September 4, 2019
by europeanpharmaceuticalreview
Endo strikes $10M opioid settlement with just 2 Ohio counties, and Allergan may not be far behind
As the closely-watched opioid litigation in Ohio nears its first trial, Endo has struck a $10 million settlement and Allergan is said to be nearing its own deal.
August 22, 2019
by fiercepharma
Endo Announces Executive VP, Chief Commercial Officer Appointment
Endo announced the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective immediately.
August 2, 2019
by americanpharmaceuticalreview
Endo Appoints EVP and CCO, Sterile and Generics
Ciarico to lead commercial strategy and execution for Endo's Generics Pharmaceutical and Sterile Injectable businesses.
August 2, 2019
by contractpharma
$70 Million Settlement Reached in Generic Drug Delay Case
Three drug companies will pay a total of nearly $70 million to California to settle charges of delaying the sale of generic drugs to keep brand-name drug prices high...
July 31, 2019
by drugs
Endo CEO Campanelli nabs almost $20M in 2018 pay, thanks to special 2017 bonus
Endo’s stock price hasn’t at all recovered from a sharp decline thanks to generics price erosion and a gloomy outlook for the company’s business. But CEO Paul Campanelli snagged a huge pay pump in 2018 anyway—and not just because the board thinks he's don
May 6, 2019
by fiercepharma
Federal judge scolds Purdue, Endo and Mallinckrodt for stall tactics in opioids case
U.S. District Judge Dan Polster has had enough of opioids makers Purdue Pharma, Endo and Mallinckrodt asking for extensions in the multistate lawsuit against them.
April 23, 2019
by fiercepharma
Endo terminates $190M deal for sterile injectable player
The Dublin-based Endo and its Par sterile injectables subsidiaries Wednesday said a $190 million agreement to buy sterile injectables company Somerset Therapeutics had been terminated without penalties because it was taking too long to complete.
March 3, 2019
by fiercepharma